View Important Safety Information

  • JOIN THE MOVEMENT

    Over one million patients worldwide have turned to XEOMIN—the latest neurotoxin for treatment of movement disorders and spasticity—and that number continues to grow.1*

    Left: Jan, cervical dystonia patient
    Right: Dona, blepharospasm patient

    Center: Ruben, upper limb spasticity patient

    Read patient stories

At Merz—the company behind XEOMIN—we understand the struggles and the unique needs of adult patients with upper limb spasticity, cervical dystonia, and blepharospasm. We are committed to helping you achieve a better patient experience. We recognize that you have your own unique goals and aspirations. We want to help you focus on your next adventure, next achievement, or next opportunity—not your symptoms.
Read more about XEOMIN.

*Patients used XEOMIN for other indications in addition to cervical dystonia, blepharospasm, and upper limb spasticity in adults.

Reference

  1. Data on file. Raleigh, NC: Merz Pharmaceuticals, LLC.
Please Confirm